MRNA

NASD Moderna, Inc.

Oct 23, 2026 · 11:10 AM ET DELAYED Market Open

$200.20 ↓ -2.43 (-1.20%) Trading Down from the previous close of $202.63, $3.27 below the day’s high of $203.47

YTD change: +578.88%
vs 20-day SMA: -4.86%
vs 200-day SMA: +146.12%

Price ranges

Previous day

$180.80 $241.26

open $240.00 close $202.63

-$37.37 (-15.57%)

Today

$183.00 $203.47

open $197.52 now $200.20

+$2.68 (+1.36%)

Past week

$180.80 $254.48

from $236.50 now $200.20

-$36.30 (-15.35%)

Past month

$180.80 $254.48

from $194.82 now $200.20

+$5.38 (+2.76%)

This year

$29.49 $254.48

from $29.49 now $200.20

+$170.71 (+578.88%)

Price & Performance

+149.78 (+283.41%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Neutral

The stock is 59.8% away from all-time highs of $497.49
MRNA is up 579% since the beginning of the year
MRNA is up 663% over the past 12 months
MRNA is up 3% over the past 1 month
8% of all MRNA investors are betting against MRNA

MRNA reads neutral: price sits above one of the two key moving averages, the 12-month move is +671.9%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No

EPS $-1.97

Earnings momentum -76.9% Quarterly EPS growth

Quarterly change -76.9%

Valuation

P/E ratio N/A

Enterprise value $76.8B

Beta 0.33

Balance sheet & scale

IncomeN/A

Revenue$2.2B

Cash$5.1B

Debt$1.3M

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD

Sector Professional, Scientific, and Technical Services

Industry Group Scientific Research and Development Services

Market cap $79.9B

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Competitor comparison

Ticker	Company	Price	Change
AMGN	Amgen Inc.	$447.28	+2.04%
RVMD	Revolution Medicines, Inc.	$187.69	-3.39%
ROIV	Roivant Sciences Ltd.	$37.45	+1.77%
BNTX	BioNTech SE Sponsored ADR	$89.67	-1.77%
MEDP	Medpace Holdings, Inc.	$653.96	-1.29%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.